Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma Vaccines
Reports advance knowledge in melanoma vaccines research
September 14th, 2005
Reports from the United States highlight recent research on melanoma vaccines. Study 1: Autoimmune toxicities are associated with the administration of antitumor vaccines and low-dose interleukin-2 (IL-2). "The purpose of this investigation was to evaluate the occurrence of autoimmune toxicities associated with the administration of low-dose IL-2 in conjunction with vaccines for melanoma. Ninety-three patients with stage IIB, III, or IV melanoma were enrolled in three clinical trials and received anti-melanoma vaccines on days 1, 8, 15, 29, 36, and 43. The vaccines comprised peptide-pulsed dendritic cells, autologous tumor cells with GM-CSF in...
Source: Vaccine Weekly (2005-09-14)
|
